Genmab A/S Stock Earnings Estimates Lifted by HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright boosted their FY2027 earnings estimates for shares of Genmab A/S in a research report issued on Wednesday, October 7th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $1.59 per share for the year, up from their prior estimate of $1.48. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.21 per share.

Other research analysts also recently issued reports about the stock. TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and upped their target price for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Guggenheim boosted their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Monday. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Finally, Truist Financial boosted their price target on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Genmab A/S Trading Down 3.0%

GMAB opened at $36.65 on Thursday. The firm’s 50 day moving average is $33.30 and its 200-day moving average is $29.22. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $40.17. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $22.87 billion, a P/E ratio of 28.86, a P/E/G ratio of 2.05 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership raised its stake in shares of Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after purchasing an additional 921,700 shares during the last quarter. First Trust Advisors LP raised its position in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,126,069 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after purchasing an additional 35,588 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Genmab A/S by 1.8% in the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after purchasing an additional 2,637 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.